Search company, investor...

Predict your next investment

Danaher company logo
Corporation
HEALTHCARE | Medical Devices & Equipment / Device Design & Manufacturing
danaher.com

Investments

3

Portfolio Exits

6

Partners & Customers

9

About Danaher

Danaher (NYSE: DHR) is a science and technology company that designs, manufactures, and markets products and services to professional, medical, industrial, environmental, and commercial customers. It offers four strategic platforms Life Sciences, Diagnostics, Water Quality, and Product Identification. The company was founded in 1984 and is based in Washington, DC.

Headquarters Location

2200 Pennsylvania Avenue, NW Suite 800W

Washington, DC, 20037,

United States

202-828-0850

Want to inform investors similar to Danaher about your company?

Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.

Expert Collections containing Danaher

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Find Danaher in 1 Expert Collection, including Fortune 500 Investor list.

F

Fortune 500 Investor list

590 items

This is a collection of investors named in the 2019 Fortune 500 list of companies. All CB Insights profiles for active investment arms of a Fortune 500 company are included.

Latest Danaher News

Global Optogenetics Market Report 2023: Major Players Include Elliot Scientific, Shanghai Laser & Optics Century, GenSight Biologics and Danaher

Jun 8, 2023

News provided by Share this article Share this article DUBLIN, June 7, 2023 /PRNewswire/ -- The "Optogenetics Global Market Report 2023" report has been added to  ResearchAndMarkets.com's offering. This report provides strategists, marketers and senior management with the critical information they need to assess the market. The global optogenetics market is expected to grow from $28.15 billion in 2022 to $32.26 billion in 2023 at a compound annual growth rate (CAGR) of 14.6%. The optogenetics market is expected to grow to $54.24 billion in 2027 at a CAGR of 13.9%. Major players in the optogenetics market are Elliot Scientific Ltd., Shanghai Laser & Optics Century Co. Ltd., GenSight Biologics, Danaher Corporation, Coherent Inc., Thorlabs Inc., Prizmatix Ltd., Bruker Corporation, Judges Scientific Plc., Merck KGaA, The Jackson Laboratory, Noldus Information Technology BV, Applied Genetic Technologies Corporation, Circuit Therapeutics Inc., Bionic Sight LLC, Teledyne Photometrics, Campden Instruments, and Nanoscope Therapeutics Inc. Reasons to Purchase Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies. Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates. Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market. Measure the impact of high global inflation on market growth. Create regional and country strategies on the basis of local data and analysis. Identify growth segments for investment. Outperform competitors using forecast data and the drivers and trends shaping the market. Understand customers based on the latest market shares. Benchmark performance against key competitors. Suitable for supporting your internal and external presentations with reliable high quality data and analysis Optogenetics is a comprehensive technique that uses optical systems and genetic engineering technologies to accurately regulate and monitor the biological processes of a cell, group of cells, tissues, or organ with high temporal and spatial resolution. Optogenetics is to monitor and control the physiological activity of neurons and other cell types that include light sensors frequently employed to identify the underlying causes of ailments like Parkinson's, memory illnesses, anxiety, addiction issues, mood swings, and other conditions. The main products of optogenetics include lasers, actuators and sensors. Laser refers to a device that emits light through a process of optical amplification at particular wavelengths producing a very narrow beam of light. Their various applications include neuroscience, behavioral tracking, retinal disease treatment and others for use by end-users such as hospitals and clinics, diagnostics centers, research centers and others. The development of innovative systems is the key trend gaining popularity in the optogenetics market. Major companies operating in the optogenetics market are developing innovative optogenetics tools and systems with cutting-edge technologies to sustain their position in the market. For instance, in June 2022, Bruker Corporation, a US-based optogenetics tool manufacturer company launched NeuraLight 3D Ultra, an enhanced 3D holographic stimulation for optogenetics module to support advanced neuroscience and optogenetics research applications on Bruker's Ultima 2Pplus Multiphoton Microscope. NeuraLight 3D Ultra offers cutting-edge 3D holographic photostimulation tailored for in-depth functional research on neural networks and brain computation. In September 2021, Novartis AG, a Switzerland-based pharmaceutical corporation acquired Arctos Medical AG for an undisclosed amount. This acquisition aims to increase Novartis' presence in ophthalmology and strengthen its position in AAV-based gene therapy and provide patients with severe vision loss with novel treatments. Arctos Medical is a Switzerland-based gene therapy start-up company specializing in optogenetics therapies. North America was the largest region in the optogenetics market in 2022. The regions covered in the optogenetics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the optogenetics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The rising cases of Parkinson's disease and epilepsy across the world are expected to propel the growth of the optogenetics market going forward. Parkinson's disease (PD) is defined as a degenerative condition of the brain that causes motor symptoms like slow movement tremors, rigidity, and imbalance in addition to other problems like cognitive decline, mental health issues, sleep issues, pain, and sensory disturbances. Epilepsy is a brain condition that results in seizures. In optogenetic therapy, proteins that respond to specific wavelengths of light are used to treat Parkinson's disease. These proteins can be produced using gene therapy techniques to either activate or inactivate when exposed to specific types of light, ultimately leading to the normalization of brain function in Parkinson's disease (PD). The optogenetics market consists of sales of optical cannula, fiber-optic cable, and light sources. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. Key Topics Covered:

Danaher Investments

3 Investments

Danaher has made 3 investments. Their latest investment was in DNA Script as part of their Series C on October 10, 2021.

CBI Logo

Danaher Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

10/26/2021

Series C

DNA Script

$165M

No

17

7/29/2020

Series B - II

Subscribe to see more

$99M

Subscribe to see more

10

9/20/2004

Unattributed VC

Subscribe to see more

$99M

Subscribe to see more

0

Date

10/26/2021

7/29/2020

9/20/2004

Round

Series C

Series B - II

Unattributed VC

Company

DNA Script

Subscribe to see more

Subscribe to see more

Amount

$165M

$99M

$99M

New?

No

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

17

10

0

Danaher Portfolio Exits

6 Portfolio Exits

Danaher has 6 portfolio exits. Their latest portfolio exit was Danaher - ForteBio & SoloHill on October 21, 2019.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

10/21/2019

Divestiture

Danaher - ForteBio & SoloHill

$99M

5

9/18/2019

IPO

Subscribe to see more

$99M

Subscribe to see more

10

1/1/2019

Spinoff / Spinout

Subscribe to see more

$99M

Subscribe to see more

10

3/3/2015

Merger

Subscribe to see more

$99M

Subscribe to see more

10

2/4/2013

Acq - Fin

Subscribe to see more

$99M

Subscribe to see more

10

Date

10/21/2019

9/18/2019

1/1/2019

3/3/2015

2/4/2013

Exit

Divestiture

IPO

Spinoff / Spinout

Merger

Acq - Fin

Companies

Danaher - ForteBio & SoloHill

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Acquirer

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

5

10

10

10

10

Danaher Acquisitions

26 Acquisitions

Danaher acquired 26 companies. Their latest acquisition was Aldevron on June 17, 2021.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

6/17/2021

Private Equity

$99M

Acquired

16

6/1/2021

Grant

$99M

$36.75M

Acquired

3

7/15/2020

Debt

$99M

$5.75M

Acquired

3

2/25/2019

Subscribe to see more

$99M

Subscribe to see more

10

3/9/2018

Growth Equity

Subscribe to see more

$99M

$99M

Subscribe to see more

10

Date

6/17/2021

6/1/2021

7/15/2020

2/25/2019

3/9/2018

Investment Stage

Private Equity

Grant

Debt

Growth Equity

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Total Funding

$36.75M

$5.75M

$99M

Note

Acquired

Acquired

Acquired

Subscribe to see more

Subscribe to see more

Sources

16

3

3

10

10

Danaher Partners & Customers

9 Partners and customers

Danaher has 9 strategic partners and customers. Danaher recently partnered with University of Pennsylvania on March 3, 2023.

Date

Type

Business Partner

Country

News Snippet

Sources

3/8/2023

Partner

United States

Danaher and University of Pennsylvania partner for cell therapies

Global science and technology innovator Danaher has entered a strategic collaboration with the University of Pennsylvania for cellular immunotherapies to address manufacturing challenges impacting cell therapy uptake .

2

11/21/2022

Partner

United States

Subscribe to see more

Subscribe to see more

10

3/21/2018

Partner

United States

Subscribe to see more

Subscribe to see more

10

7/1/2017

Partner

Germany

Subscribe to see more

Subscribe to see more

10

3/8/2016

Partner

India

Subscribe to see more

Subscribe to see more

10

Date

3/8/2023

11/21/2022

3/21/2018

7/1/2017

3/8/2016

Type

Partner

Partner

Partner

Partner

Partner

Business Partner

Country

United States

United States

United States

Germany

India

News Snippet

Danaher and University of Pennsylvania partner for cell therapies

Global science and technology innovator Danaher has entered a strategic collaboration with the University of Pennsylvania for cellular immunotherapies to address manufacturing challenges impacting cell therapy uptake .

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

2

10

10

10

10

Danaher Team

40 Team Members

Danaher has 40 team members, including current Chief Executive Officer, President, H. Lawrence Culp.

Name

Work History

Title

Status

H. Lawrence Culp

Chief Executive Officer, President

Current

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Name

H. Lawrence Culp

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Work History

Title

Chief Executive Officer, President

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Current

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Compare Danaher to Competitors

Mammoth Biosciences Logo
Mammoth Biosciences

Mammoth Biosciences is a biotechnology company focused on using its ultra-compact systems to develop therapies, as well as other applications such as decentralized precision diagnostics. It aims to democratize disease detection with a point-of-care test that allows for rapid and simultaneous detection of multiple conditions. It was formerly known as Apheleia Diagnostics. The company was founded in 2017 and is based in Brisbane, California.

Roche Bros. Logo
Roche Bros.

Roche Bros. is a chain grocery store that provides foods, bakery products, seafood, catering, and home delivery services. It is based in Wellesley, Massachusetts.

Haemonetics Logo
Haemonetics

Haemonetics operates as a medical device company. It markets automated blood processing systems. The company's systems help in surgical blood salvage, blood component collections, and plasma collections. It was founded in 1971 and is based in Braintree, Massachusetts.

PixCell Medical Technologies Logo
PixCell Medical Technologies

PixCell Medical Technologies is a privately held company developing cell-based diagnostics for the point of care (POC), based on its viscoelastic focusing and microfluidics technology. The company's core technology is comprised of an analyzer and a self-contained disposable cartridge. On May 3, 2021, PixCell Medical Technologies was acquired by Soulbrain. The terms of the transaction were not disclosed.

Truvian Logo
Truvian

Truvian operates as a healthcare company. Its automated benchtop system produces lab-accurate results for a full suite of health tests using a small sample of blood. It provides lab-accurate results in less time for a comprehensive suite of health tests. It was formerly known as Salveo Dx. It was founded in 2015 and is based in San Diego, California.

S
Sight Diagnostics

Sight Diagnostics provides affordable and accurate diagnostics in a compact platform designed for use in qualified labs in low volume settings. Its proprietary machine-vision based technology provides the capability to perform multiple tests on a single, easy-to-operate platform.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.